New York State Common Retirement Fund Has $175.43 Million Stake in Amgen Inc. (NASDAQ:AMGN)

New York State Common Retirement Fund increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 673,079 shares of the medical research company's stock after buying an additional 2,084 shares during the quarter. New York State Common Retirement Fund owned approximately 0.13% of Amgen worth $175,431,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the 3rd quarter valued at $29,000. Heck Capital Advisors LLC bought a new stake in Amgen in the 4th quarter valued at $36,000. PrairieView Partners LLC raised its stake in Amgen by 118.3% in the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company's stock valued at $46,000 after acquiring an additional 97 shares during the period. Finally, Wingate Wealth Advisors Inc. bought a new stake in Amgen in the 4th quarter valued at $52,000. Institutional investors own 76.50% of the company's stock.

Insider Activity at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,405 shares of company stock worth $10,410,596 over the last ninety days. Insiders own 0.69% of the company's stock.

Amgen Trading Up 1.7 %

Shares of NASDAQ:AMGN traded up $5.08 during midday trading on Friday, hitting $303.01. 3,260,757 shares of the stock were exchanged, compared to its average volume of 3,124,757. The stock has a market capitalization of $162.78 billion, a price-to-earnings ratio of 40.13, a P/E/G ratio of 2.55 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The business's 50-day moving average price is $275.62 and its 200 day moving average price is $300.75. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts predict that Amgen Inc. will post 20.6 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.14%. Amgen's dividend payout ratio is presently 126.09%.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Piper Sandler Companies restated an "overweight" rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Redburn Partners lowered their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Wolfe Research initiated coverage on Amgen in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock. Jefferies Financial Group restated a "buy" rating and issued a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Finally, Bank of America raised their price target on Amgen from $256.00 to $275.00 and gave the stock an "underperform" rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $314.09.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.